Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
About
The specific purpose of this Notice of Funding Opportunity (NOFO) is to promote the development of a diverse, interdisciplinary workforce needed to conduct translational research on Alzheimer's disease and Alzheimer's-related dementias from target discovery through clinical development. This NOFO will support institutional training programs for predoctoral and postdoctoral level researchers with diverse educational backgrounds (i. e., basic biology, translational and clinical research, data science). The program invites eligible institutions to develop interdisciplinary training programs that will provide trainees with the knowledge and skills in data science, disease biology, behavioral research, and traditional and emerging drug discovery disciplines necessary to conduct rigorous and cutting-edge basic, translational, and clinical research for AD/ADRD.
The Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) grant supports institutions in developing comprehensive, interdisciplinary workforce training programs focused on Alzheimer's disease and related dementias research. This federal funding opportunity is designed for eligible institutions—including HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian serving institutions, and other organizations—to establish training initiatives for predoctoral and postdoctoral researchers. The program funds institutional capacity-building in translational research across multiple disciplines: basic biology, translational and clinical research, data science, behavioral research, and drug discovery. Trainees gain expertise spanning from target discovery through clinical development, preparing them to conduct rigorous, cutting-edge research in AD/ADRD. This grant is ideal for research institutions seeking to build diverse, skilled talent pipelines and advance the next generation of Alzheimer's researchers. By investing in institutional training infrastructure, organizations can strengthen their research competitiveness while contributing to critical advances in dementia prevention, diagnosis, and treatment.
Funding Facts
● Applications openDeadline
September 25, 2026
Who can apply
Last verified July 5, 2026 · Source: Grants.gov
Grant Details
Funding Range
Varies by award cycle
Deadline
2026-09-25
Grant Type
federal
Application Cycle
Annual
Best For
Institutional research training programs at eligible colleges and universities, particularly minority-serving institutions, building diverse workforce capacity in Alzheimer's disease and dementia research
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Govern
Frequently Asked Questions
Who is eligible for Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)?
Eligible applicants include Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based and community-based organizations, eligible federal government agencies, and other qualifying institutions. For complete eligibility requirements and institutional classification details, consult the official Notice of Funding Opportunity (NOFO) on the funding agency's website.
How much funding does Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) provide?
Specific funding amounts vary by award cycle and institutional factors. Contact the sponsoring agency or review the current NOFO for detailed budget information, funding ranges, and cost-sharing requirements.
How do I apply for Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)?
Applications are submitted through the agency's grants management system, typically requiring institutional authorization and documentation of training program plans. Visit the official funding agency website to access the complete NOFO, application instructions, deadlines, and required forms. Applicants should carefully review eligibility criteria and submission requirements before beginning the application process.
What can Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed) funding be used for?
Funding supports the development of institutional training programs in translational Alzheimer's disease and dementia research. Resources can support trainee stipends, tuition, and training in data science, disease biology, behavioral research, and drug discovery methodologies. Programs prepare predoctoral and postdoctoral researchers across diverse educational backgrounds for careers advancing AD/ADRD research from basic science through clinical development. Note: Clinical trials are not permitted under this mechanism.
Last updated: July 5, 2026